24 November 2023
24 November 2023
It has been 20 years since the paroxetine scandal and trial reporting has come a long way since then but there are still flaws.
Improvements have already been made, including reduction in registration time and the removal of barriers for nationally agreed costs.
The oral IBD drug was first licensed to GSK in 2020 and is currently in Phase I clinical development.
The antiviral tablet, already approved in China in January 2023, significantly reduced the time to sustained clinical symptom resolution.
The antibody received FDA orphan drug designation to treat systemic capillary leak syndrome earlier this year.
The trial will enrol around ten patients at sites in Australia and the US.
The UK’s Autumn 2023 Statement takes a special interest in revitalising parts of the life sciences scene.
The company aims to publish the first results from the trial next year.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
